# Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)

> **NCT00429754** · PHASE4 · WITHDRAWN · sponsor: **Radboud University Medical Center**

## Conditions studied

- Nausea
- Vomiting

## Interventions

- **DRUG:** Aprepitant

## Key facts

- **NCT ID:** NCT00429754
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2008-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** change of study population and chemotherapeutic regimen
- **Last updated:** 2016-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429754, "Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00429754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*